posted
Oncology Med Announces Its First Quarter 2007 Unaudited Results Wednesday June 13, 9:45 am ET
Revenues Increase 32% From Prior Year
PITTSBURGH, PA--(MARKET WIRE)--Jun 13, 2007 -- Oncology Med, Inc. (Other OTC:ONCO.PK - News) announced its unaudited results for the first quarter ended March 31, 2007. Revenues were $ 437,219.65 for the three-month period ended March 31, 2007 which represented a 32% increase from revenues of $ 331,511.84 for the three-month period ended March 31, 2006. Excluding a one-time charge for a prior bad debt, Net Income was $ 33,560.64 for the three-month period ended March 31, 2007 as compared to a Net Loss of $ 39,739.29 for the three-month period ended March 31, 2006. ADVERTISEMENT
Dr. William J. Walker, chairman of Oncology Med, Inc., stated, "I am extremely pleased with our unaudited results for the first quarter, 2007. We have achieved a substantial increase in revenue over the same period last year which has resulted in net income for the first quarter, 2007. Our roll out of our IMRT program is achieving immediate results as our revenues increase. As clients get more comfortable with the potential revenue increases they will achieve by offering IMRT treatment plans to patients, their use of IMRT treatment programs will increase which should result in our continuing growth."
About Oncology Med, Inc.
Oncology Med is a public company engaged in the fulfillment of services related to the treatment of various cancers. It currently provides analysis and design of radiation treatment plans in order for radiation oncologists to administer radiation plans to cancer patients. Current services facilitate radiation treatment programs ranging from external beam radiation to more advanced radiation treatment technologies.
NOTE: This press release may contain "forward-looking statements." In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "potential," "continue" or the negative of such terms and other comparable terminology. These forward-looking statements include, without limitation, statements about our market opportunity, our strategies, competition, expected activities and expenditures as we pursue our business plan, and the adequacy of our available cash resources. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Actual results may differ materially from the predictions discussed in these forward-looking statements. Changes in the circumstances upon which we base our predictions and/or forward-looking statements could materially affect our actual results.
Contact: For information, please contact: Mr. Trevor Bentley Investor Communications Bentley Communications 1-888-818-8738 Email Contact
IP: Logged |
posted
[/b]Posted by: SelTzer In reply to: redsoxnumba1 who wrote msg# 1008 Date:1/28/2008 9:21:26 PM Post #of 1020
These guys are the hottest micro cap stock pickers on the internet. Looks like they see the same thing you see. Looks like double digits on the way. Check it out, good choice.
February Company of the Month EricDavid & Sons, Inc rates Oncology Med, Inc (PinkSheets: ONCO) "Aggressive out perform Strong Buy"
(PINKSHEETS: ONCO) Shares Authorized 200Mil Shares Outstanding 61Mil Est Public Float 25Mil 52 week high $1.28 52 week low $0.009 January 28th closing price $0.034
Dear Readers,
I came across two very nice public companies which are both in the very same business of Radiation Therapy Services Centers. The only thing different is that one company is a giant in this field and the other is a start up. The amazing thing about these two companies is that they are the only public companies in this sector. Radiation Therapy Services (NASDAQ:RTSX) currently trading at $27.32 had been a monopoly the only public company in the industry. RTSX did $100million in revenue for their 2nd QT earning a net income of $10Million. Now get a load of this, on Oct 19, 2007 Vestor Capital Partners agreed to acquire RTSX for a whopping $32.50 a share a deal worth $1.1 Billion dollars.
Now comes along our little unknown gem in the exact same medical field doing the exact same thing as RTSX. Oncology Med, Inc (PINKSHEETS: ONCO) This beauty of a Company has already secured two million dollars in Contracts and is aggressively expanding their Radiation Therapy Services Centers in PA and OH. Could this little baby become the very next RTSX? Well that’s why EDS profiles, follows and brings you these unique Companies which in fact can become the next Wall Street darlings. When you read this Company Profile, I am sure that you will see what we’ve discovered for you in an undervalued situation.
Oncology Med, Inc. is a public company engaged in the fulfillment of a variety of services related to the treatment of various cancers. We currently provide analysis and design of radiation treatment plans in order for radiation oncologists to administer various radiation treatment plans to cancer patients. Our services facilitate radiation treatment programs ranging from external beam radiation to more advanced radiation treatment technologies.
Our mission is to be a pioneer in the advancement of the treatment of cancers. We plan on growing our business through acquisitions in addition to the organic growth of our subsidiary, Comprehensive Physics and Regulatory Services (“CPRS”).
CPRS has pioneered the use of the internet for clinical radiation oncology treatment planning. The service was commenced over ten years ago in an effort to provide cost effective treatment planning by smaller radiation/cancer centers through the sharing of expertise and resources. Medical records including MRI and X-Rays are sent over the internet which allow our staff of physicists and dosemitrists to turn around a fully developed treatment plan in less that 24 hours.
Today our clients range from world class cancer treatment centers to local and regional cancer treatment centers. We have continued to grow in the scope of our services offered and in the geographical areas served, supporting over 25 radiation oncology centers from Florida to New England. Expansion opportunities exist both domestically and internationally.
Our team consists of industry professionals from many countries around the world. We leverage our experience through collaboration, professional development, training and technology. Our organizational structure is comprised of Physicists, Dosimetrists, Radiation Oncologists, Medical Technologists and Medical Business Consultants.
William J. Walker, Ph.D., CHP , PE Chairman of the Board
Dr. Walker is Chairman of the Board of Oncology Med. Inc., and is President and Chief Executive Officer of Comprehensive Physics & Regulatory Services, Ltd. (“CPRS”). Dr. Walker is a medical physicist with over 40 years of clinical practice, research and program management. He holds a B.S. in Civil Engineering from the Virginia Military Institute, an M.S. in Radiation Biophysics from the University of Kansas, and a Ph. D. from the University of Florida in Environmental Engineering (Medical Physics). He is certified by the American Board of Health Physics, licensed by the State of Florida as a Therapeutic Radiological Physicist and is a registered professional engineer. Dr. Walker retired from the U.S. Air Force in 1978 as a Lt. Col. And was the Chief of Medical Physics for a major USAF Medical Center. Following his retirement from the Air Force, he headed the US Nuclear Regulatory Commission’s medical and academic licensing program and later was the Radiation Safety Officer and Program Director for the National Institute of Health, the largest such program of its kind in the world. He is the author of numerous papers on medical and health physics and a corporate officer and member of the Board of Directors of Advanced Oncology Network, Inc. Dr. Walker is additionally a member of the Boards of Directors of Eureka Cancer Treatment Center, Ltd. and Universal Healthcare Management Systems, Inc.
G. Stephen Brown, M.D., FACR
Dr. Brown is a Professor of Radiation Oncology at the University of Texas M.D. Anderson Cancer Center in Houston. His professional activities are dedicated entirely to peer review and standard applications in Cancer treatments. He received his B.A. in zoology from U.C.L.A. and his M.D. from the University of Ottowa Faculty of Medicine in 1963. After serving a general rotating internship at Cedars-Sinai Medical Center in Los Angeles, he began a 4 year residency in radiation oncology. The first year was at the Cedars – Sinai Medical Center, Los Angeles, CA. The remaining three years were at the Penrose Cancer Hospital in Colorado Springs, CO. The final five months were at the Puerto Rico Nuclear Center in San Juan, Puerto Rico.
After achieving board certification in Therapeutic Radiology from the American Board of Radiology in 1968, he entered practice at the University of Vermont. He served in the U.S. Army Medical Corps at the rank of Major from 1969 to 1972 where he served as Chief of Radiation Therapy and Chief of Nuclear Medicine, Honolulu, Hawaii. He returned to the University of Vermont as Director of Radiation Oncology through 1977. He wss in private practice of radiation oncology from 1977-1990. He was a consultant to the Cancer Department of the World Health Organization from 1990 – 1991. From 1992-1993 he was Associate Director, Division of Cancer Treatment, Radiation Research Branch at the National Cancer Institute. From 1993-1995 he served as Medical Director of Oncology Services Corporation. Since 1995, he has been the Associate Director for Radiation Oncology at the UT M.D..
Mitchell Jarosz, M.S., DABR
Mr. Jarosz received his BS in physics from Duquesne University and attended the Carnegie Mellon Institute for his MS in Radiological Physics. He worked as a staff physicist at St. Francis Medical Center, Pittsburgh, PA for 16 years where he gained experience in commissioning and maintaining various types of radiation therapy equipment,. His experience includes beam data collection, entry and commissioning of treatment planning computers including: ADAC, Multimedia, CMS and Medicalibration PC#D. He is experienced in performing diagnostic calibrations on various x-ray systems including R/F, CT (GE, Elscint, Siemens and Picker), dental ultrasound and mammography units. He has established quality assurance programs and physics protocols for a number of centers for a variety of treatment modalities. He has held course of instruction in diagnostic radiology and nuclear medicine for residents and technologists.
I’m sure you enjoyed this read and that you agree we are on to something great. Keep a look out for our text interview with the CEO next week.
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
